Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

July 26, 2022; 99 (4) Research Article

Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes

Pashtun Shahim, View ORCID ProfileHenrik Zetterberg, Joel Simrén, View ORCID ProfileNicholas J. Ashton, Gina Norato, View ORCID ProfileMichael Schöll, Yelverton Tegner, Ramon Diaz-Arrastia, View ORCID ProfileKaj Blennow
First published June 2, 2022, DOI: https://doi.org/10.1212/WNL.0000000000200615
Pashtun Shahim
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Zetterberg
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Henrik Zetterberg
Joel Simrén
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas J. Ashton
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas J. Ashton
Gina Norato
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Schöll
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael Schöll
Yelverton Tegner
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramon Diaz-Arrastia
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaj Blennow
From the Institute of Neuroscience and Physiology (P.S., H.Z., J.S., N.J.A., M.S., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (P.S., H.Z., J.S., N.J.A., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Rehabilitation Medicine Department (P.S.), National Institutes of Health Clinical Center, Bethesda, MD; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, United Kingdom; UK Dementia Research Institute (H.Z.), London; Wallenberg Centre for Molecular and Translational Medicine (N.J.A., M.S.), University of Gothenburg, Sweden; King's College London (N.J.A.), Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute; NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation (N.J.A.), United Kingdom; Clinical Trials Unit (G.N.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Division of Health (Y.T.), Medicine and Rehabilitation, Department of Health Science, Luleå University of Technology, Sweden; and Department of Neurology (R.D.-A.), University of Pennsylvania Perelman School of Medicine, Philadelphia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kaj Blennow
Full PDF
Short Form
Citation
Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes
Pashtun Shahim, Henrik Zetterberg, Joel Simrén, Nicholas J. Ashton, Gina Norato, Michael Schöll, Yelverton Tegner, Ramon Diaz-Arrastia, Kaj Blennow
Neurology Jul 2022, 99 (4) e347-e354; DOI: 10.1212/WNL.0000000000200615

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
124

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Background and Objectives To examine whether the brain biomarkers total-tau (T-tau), glial fibrillary acidic protein (GFAP), and β-amyloid (Aβ) isomers 40 and 42 in plasma relate to the corresponding concentrations in CSF, blood-brain barrier integrity, and duration of postconcussion syndrome (PCS) due to repetitive head impacts (RHIs) in professional athletes.

Method In this cross-sectional study, professional athletes with persistent PCS due to RHI (median of 1.5 years after recent concussion) and uninjured controls were assessed with blood and CSF sampling. The diagnosis of PCS was based on the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). The athletes were enrolled through information flyers about the study sent to the Swedish Hockey League (SHL) and the SHL Medicine Committee. The controls were enrolled through flyers at University of Gothenburg and Sahlgrenska University Hospital, Sweden. The participants underwent lumbar puncture and blood assessment at Sahlgrenska University Hospital. The main outcome measures were history of RHI and PCS severity (PCS >1 year vs PCS <1 year) in relation to plasma and CSF concentrations of T-tau, GFAP, Aβ40, and Aβ42. Plasma T-tau, GFAP, Aβ40, and Aβ42 were quantified using an ultrasensitive assay technology.

Results A total of 47 participants (28 athletes [median age 28 years, range 18–52] with persistent PCS due to RHI and 19 controls [median age, 25 years, range 21–35]) underwent paired blood and CSF sampling. T-tau, Aβ40, and Aβ42 concentrations measured in plasma did not correlate with the corresponding CSF concentrations, while there was a correlation between plasma and CSF levels of GFAP (r = 0.45, p = 0.020). There were no significant relationships between plasma T-tau, GFAP, and blood-brain barrier integrity as measured by the CSF:serum albumin ratio. T-tau, GFAP, Aβ40, and Aβ42 measured in plasma did not relate to PCS severity. None of the markers measured in plasma correlated with number of concussions, except decreased Aβ42 in those with higher number of concussions (r = −0.40, p = 0.04).

Discussion T-tau, GFAP, Aβ40, and Aβ42 measured in plasma do not correspond to CSF measures and may have limited utility for the evaluation of the late effects of RHI, compared with when measured in CSF.

Classification of Evidence This study provides Class III evidence that in professional athletes with postconcussion symptoms, plasma concentrations of T-tau, GFAP, Aβ40, and Aβ42 are not informative in the diagnosis of late effects of repetitive head injuries.

Glossary

Aβ=
β-amyloid;
AD=
Alzheimer disease;
GFAP=
glial fibrillary acidic protein;
LP=
lumbar puncture;
PCS=
postconcussive syndrome;
RHI=
repetitive head impact;
RPQ=
Rivermead Post-Concussion Symptom Questionnaire;
SHL=
Swedish Hockey League;
TBI=
traumatic brain injury;
T-tau=
total-tau

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • Submitted and externally peer reviewed. The handling editor was Rebecca Burch, MD.

  • See page e427

  • Class of Evidence: NPub.org/coe

  • Received April 20, 2021.
  • Accepted in final form March 15, 2022.
  • © 2022 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Study Funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Costs and Utilization of New-to-Market Neurologic Medications

Dr. Robert J. Fox and Dr. Mandy Leonard

► Watch

Related Articles

  • Can We Measure Brain Injury With a Blood Test?
  • Spotlight on the July 26 Issue

Alert Me

  • Alert me when eletters are published
Neurology: 101 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise